文章：

异基因造血干细胞移植后的长期并发症和副作用：最新进展

Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update

原文发布日期：2011-04-29

DOI: 10.1038/bcj.2011.14

类型: Review

开放获取: 是

英文摘要：

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective therapy for various malignant and non-malignant diseases. Many patients have now been followed for two or three decades posttransplant and are presumed to be cured. With the tremendous advances achieved in terms of supportive care, it is reasonable to expect outcomes to improve steadily and consequently increasing numbers of transplant survivors will be facing life after the initial transplant experience. Although long-term allo-HSCT survivors generally enjoy good health, for many others, cure or control of the underlying disease is not accompanied by full restoration of health. The burden of long-term morbidity borne by allo-HSCT survivors is substantial, and long-term follow-up of patients who received allo-HSCT is now widely recommended. Immediate survival is no longer the sole concern after allo-HSCT. The goals should also include complete recovery of the overall health status with normal physical and psychological functioning. Long-term side effects after allo-HSCT include non-malignant organ or tissue dysfunction, changes in quality of life, infections related to abnormal immune reconstitution and secondary cancers. Many of these can be attributed to the deleterious effects of chronic graft-versus-host disease. The aims of this review are to provide an update on the recent research evidence in the field.

摘要翻译： 

异基因造血干细胞移植（allo-HSCT）是治疗各种恶性与非恶性疾病的有效方法。目前许多移植术后患者已被随访二至三十年，且被视为临床治愈。随着支持治疗的巨大进步，合理预期疗效将稳步提升，移植幸存者数量亦将随之增长。尽管长期存活者通常健康状况良好，但对许多患者而言，原发病的治愈或控制并未伴随健康的完全恢复。移植幸存者承担着显著的长期病患负担，因此对移植受者进行长期随访已被广泛推荐。移植后的关注焦点已不再局限于短期存活，更应追求包括生理心理功能完全恢复在内的整体健康状态重建。移植后的长期副作用包括非恶性器官/组织功能异常、生活质量改变、免疫重建异常相关感染及继发性肿瘤。这些后遗症多与慢性移植物抗宿主病的持续损害相关。本文旨在综述该领域最新研究进展。

原文链接：

Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update